Ovarian ablation for premenopausal early-stage breast cancer: An update

Luigi Celio, Emilio Bajetta, Luisa Toffolatti, Laura Catena, Elena Beretta, Roberto Buzzoni

Research output: Contribution to journalArticle

Abstract

Ovarian ablation is the oldest form of systemic treatment of breast cancer and consists of removal of the main source of estrogen biosynthesis in premenopausal women. Over the last century several different means of stopping ovarian function have been studied: surgical oophorectomy, ovarian irradiation, and more recently, chemical castration by gonadotropin-releasing hormone analog therapy. In unselected patients the response rate to ovarian ablation is of about 35% but the likelihood of response is considerably higher for patients with hormonal receptor-positive tumors, the therapy being most effective in women who are actively menstruating. In spite of this evidence, the role of ovarian ablation in the management of early-stage breast cancer still remains controversial. Here we review current evidence supporting the value of this ablative procedure as an adjuvant and update ongoing clinical research to refine our knowledge about its use.

Original languageEnglish
Pages (from-to)191-194
Number of pages4
JournalTumori
Volume86
Issue number3
Publication statusPublished - May 2000

Fingerprint

Breast Neoplasms
Castration
Ovariectomy
Gonadotropin-Releasing Hormone
Estrogens
Therapeutics
Research
Neoplasms

Keywords

  • Adjuvant therapy
  • Early breast cancer
  • Ovarian ablation
  • Premenopausal women

ASJC Scopus subject areas

  • Cancer Research

Cite this

Celio, L., Bajetta, E., Toffolatti, L., Catena, L., Beretta, E., & Buzzoni, R. (2000). Ovarian ablation for premenopausal early-stage breast cancer: An update. Tumori, 86(3), 191-194.

Ovarian ablation for premenopausal early-stage breast cancer : An update. / Celio, Luigi; Bajetta, Emilio; Toffolatti, Luisa; Catena, Laura; Beretta, Elena; Buzzoni, Roberto.

In: Tumori, Vol. 86, No. 3, 05.2000, p. 191-194.

Research output: Contribution to journalArticle

Celio, L, Bajetta, E, Toffolatti, L, Catena, L, Beretta, E & Buzzoni, R 2000, 'Ovarian ablation for premenopausal early-stage breast cancer: An update', Tumori, vol. 86, no. 3, pp. 191-194.
Celio L, Bajetta E, Toffolatti L, Catena L, Beretta E, Buzzoni R. Ovarian ablation for premenopausal early-stage breast cancer: An update. Tumori. 2000 May;86(3):191-194.
Celio, Luigi ; Bajetta, Emilio ; Toffolatti, Luisa ; Catena, Laura ; Beretta, Elena ; Buzzoni, Roberto. / Ovarian ablation for premenopausal early-stage breast cancer : An update. In: Tumori. 2000 ; Vol. 86, No. 3. pp. 191-194.
@article{03f687d6cb5846f587d539c845dd077b,
title = "Ovarian ablation for premenopausal early-stage breast cancer: An update",
abstract = "Ovarian ablation is the oldest form of systemic treatment of breast cancer and consists of removal of the main source of estrogen biosynthesis in premenopausal women. Over the last century several different means of stopping ovarian function have been studied: surgical oophorectomy, ovarian irradiation, and more recently, chemical castration by gonadotropin-releasing hormone analog therapy. In unselected patients the response rate to ovarian ablation is of about 35{\%} but the likelihood of response is considerably higher for patients with hormonal receptor-positive tumors, the therapy being most effective in women who are actively menstruating. In spite of this evidence, the role of ovarian ablation in the management of early-stage breast cancer still remains controversial. Here we review current evidence supporting the value of this ablative procedure as an adjuvant and update ongoing clinical research to refine our knowledge about its use.",
keywords = "Adjuvant therapy, Early breast cancer, Ovarian ablation, Premenopausal women",
author = "Luigi Celio and Emilio Bajetta and Luisa Toffolatti and Laura Catena and Elena Beretta and Roberto Buzzoni",
year = "2000",
month = "5",
language = "English",
volume = "86",
pages = "191--194",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Ovarian ablation for premenopausal early-stage breast cancer

T2 - An update

AU - Celio, Luigi

AU - Bajetta, Emilio

AU - Toffolatti, Luisa

AU - Catena, Laura

AU - Beretta, Elena

AU - Buzzoni, Roberto

PY - 2000/5

Y1 - 2000/5

N2 - Ovarian ablation is the oldest form of systemic treatment of breast cancer and consists of removal of the main source of estrogen biosynthesis in premenopausal women. Over the last century several different means of stopping ovarian function have been studied: surgical oophorectomy, ovarian irradiation, and more recently, chemical castration by gonadotropin-releasing hormone analog therapy. In unselected patients the response rate to ovarian ablation is of about 35% but the likelihood of response is considerably higher for patients with hormonal receptor-positive tumors, the therapy being most effective in women who are actively menstruating. In spite of this evidence, the role of ovarian ablation in the management of early-stage breast cancer still remains controversial. Here we review current evidence supporting the value of this ablative procedure as an adjuvant and update ongoing clinical research to refine our knowledge about its use.

AB - Ovarian ablation is the oldest form of systemic treatment of breast cancer and consists of removal of the main source of estrogen biosynthesis in premenopausal women. Over the last century several different means of stopping ovarian function have been studied: surgical oophorectomy, ovarian irradiation, and more recently, chemical castration by gonadotropin-releasing hormone analog therapy. In unselected patients the response rate to ovarian ablation is of about 35% but the likelihood of response is considerably higher for patients with hormonal receptor-positive tumors, the therapy being most effective in women who are actively menstruating. In spite of this evidence, the role of ovarian ablation in the management of early-stage breast cancer still remains controversial. Here we review current evidence supporting the value of this ablative procedure as an adjuvant and update ongoing clinical research to refine our knowledge about its use.

KW - Adjuvant therapy

KW - Early breast cancer

KW - Ovarian ablation

KW - Premenopausal women

UR - http://www.scopus.com/inward/record.url?scp=0033927670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033927670&partnerID=8YFLogxK

M3 - Article

C2 - 10939596

AN - SCOPUS:0033927670

VL - 86

SP - 191

EP - 194

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 3

ER -